Anavex Life Sciences (FRA:12X1) Interest Expense : €-0.90 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Anavex Life Sciences Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Anavex Life Sciences's interest expense for the three months ended in Dec. 2023 was € 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.90 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Anavex Life Sciences's Operating Income for the three months ended in Dec. 2023 was € -10.36 Mil. Anavex Life Sciences's Interest Expense for the three months ended in Dec. 2023 was € 0.00 Mil. Anavex Life Sciences has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Anavex Life Sciences Interest Expense Historical Data

The historical data trend for Anavex Life Sciences's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anavex Life Sciences Interest Expense Chart

Anavex Life Sciences Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Interest Expense

Get a 7-Day Free Trial

-0.14

-0.90

Anavex Life Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-	-0.90	-	-	-

Anavex Life Sciences Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.90 Mil.

Anavex Life Sciences (FRA:12X1) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Anavex Life Sciences's Interest Expense for the three months ended in Dec. 2023 was €0.00 Mil. Its Operating Income for the three months ended in Dec. 2023 was €-10.36 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was €0.00 Mil.

Anavex Life Sciences's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Anavex Life Sciences had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Anavex Life Sciences (FRA:12X1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anavex Life Sciences Corp (FRA:12X1) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

AVXL:USA

Address

630 5th Avenue, 20th Floor, New York, NY, USA, 10111

Website

https://www.anavex.com

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.

Anavex Life Sciences (FRA:12X1) Headlines

No Headlines